Evaluating IP Blacklists Effectiveness

IP blacklists are widely used to increase network security by preventing communications with peers that have been marked as malicious. There are several commercial offerings as well as several free-of-charge blacklists maintained by volunteers on the web. Despite their wide adoption, the effectiveness of the different IP blacklists in real-world scenarios is still not clear. In this paper, we conduct a large-scale network monitoring study which provides insightful findings regarding the effectiveness of blacklists. The results collected over several hundred thousand IP hosts belonging to three distinct large production networks highlight that blacklists are often tuned for precision, with the result that many malicious activities, such as scanning, are completely undetected. The proposed instrumentation approach to detect IP scanning and suspicious activities is implemented with home-grown and open-source software. Our tools enable the creation of blacklists without the security risks posed by the deployment of honeypots

N2N: A layer two peer-to-peer VPN

Abstract. The Internet was originally designed as a flat data network delivering a multitude of protocols and services between equal peers. Currently, after an explosive growth fostered by enormous and heterogeneous economic interests, it has become a constrained network severely enforcing client-server communication where addressing plans, packet routing, security policies and users' reachability are almost entirely managed and limited by access providers. From the user's perspective, the Internet is not an open transport system, but rather a telephony-like communication medium for content consumption. This paper describes the design and implementation of a new type of peer-topeer virtual private network that can allow users to overcome some of these limitations. N2N users can create and manage their own secure and geographically distributed overlay network without the need for central administration, typical of most virtual private network systems

Exploiting the 1-(4-fluorobenzyl)piperazine fragment for the development of novel tyrosinase inhibitors as anti-melanogenic agents: Design, synthesis, structural insights and biological profile

The development of Tyrosinase inhibitors (TYRIs) could represent an efficacious strategy for pharmacological intervention on skin pathologies related to aberrant production of melanin. Based on in silico studies we designed and tested a library of twenty-four compounds bearing the 4-(4-fluorobenzyl)piperazin-1-yl]-fragment. As result, we identified several compounds with excellent inhibit effects at low micromolar concentration against TYR from Agaricus bisporus (TyM). Among them, compound 25 (IC50 = 0.96 μM) proved to be ∼20-fold more potent than the reference compound kojic acid (IC50 = 17.76 μM) having wide applications in the cosmetics and pharmaceutical industries. The mode of interaction of active inhibitor 25 was deciphered by means of crystallography as well as molecular docking and these results were consistent with kinetic experiments. Moreover, the identified compound 25 exhibited no considerable cytotoxicity and showed anti-melanogenic effects on B16F10 melanoma cells. Therefore, a combination of computational and biochemical approaches could represent a rational guidelines for further structural modification of this class of compounds as future anti-melanogenic agents

Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis

Importance: Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment of highly active multiple sclerosis (MS). Objective: To compare the effectiveness of AHSCT vs fingolimod, natalizumab, and ocrelizumab in relapsing-remitting MS by emulating pairwise trials. Design, Setting, and Participants: This comparative treatment effectiveness study included 6 specialist MS centers with AHSCT programs and international MSBase registry between 2006 and 2021. The study included patients with relapsing-remitting MS treated with AHSCT, fingolimod, natalizumab, or ocrelizumab with 2 or more years study follow-up including 2 or more disability assessments. Patients were matched on a propensity score derived from clinical and demographic characteristics. Exposure: AHSCT vs fingolimod, natalizumab, or ocrelizumab. Main outcomes: Pairwise-censored groups were compared on annualized relapse rates (ARR) and freedom from relapses and 6-month confirmed Expanded Disability Status Scale (EDSS) score worsening and improvement. Results: Of 4915 individuals, 167 were treated with AHSCT; 2558, fingolimod; 1490, natalizumab; and 700, ocrelizumab. The prematch AHSCT cohort was younger and with greater disability than the fingolimod, natalizumab, and ocrelizumab cohorts; the matched groups were closely aligned. The proportion of women ranged from 65% to 70%, and the mean (SD) age ranged from 35.3 (9.4) to 37.1 (10.6) years. The mean (SD) disease duration ranged from 7.9 (5.6) to 8.7 (5.4) years, EDSS score ranged from 3.5 (1.6) to 3.9 (1.9), and frequency of relapses ranged from 0.77 (0.94) to 0.86 (0.89) in the preceding year. Compared with the fingolimod group (769 [30.0%]), AHSCT (144 [86.2%]) was associated with fewer relapses (ARR: mean [SD], 0.09 [0.30] vs 0.20 [0.44]), similar risk of disability worsening (hazard ratio [HR], 1.70; 95% CI, 0.91-3.17), and higher chance of disability improvement (HR, 2.70; 95% CI, 1.71-4.26) over 5 years. Compared with natalizumab (730 [49.0%]), AHSCT (146 [87.4%]) was associated with marginally lower ARR (mean [SD], 0.08 [0.31] vs 0.10 [0.34]), similar risk of disability worsening (HR, 1.06; 95% CI, 0.54-2.09), and higher chance of disability improvement (HR, 2.68; 95% CI, 1.72-4.18) over 5 years. AHSCT (110 [65.9%]) and ocrelizumab (343 [49.0%]) were associated with similar ARR (mean [SD], 0.09 [0.34] vs 0.06 [0.32]), disability worsening (HR, 1.77; 95% CI, 0.61-5.08), and disability improvement (HR, 1.37; 95% CI, 0.66-2.82) over 3 years. AHSCT-related mortality occurred in 1 of 159 patients (0.6%). Conclusion: In this study, the association of AHSCT with preventing relapses and facilitating recovery from disability was considerably superior to fingolimod and marginally superior to natalizumab. This study did not find evidence for difference in the effectiveness of AHSCT and ocrelizumab over a shorter available follow-up time

nProbe: an Open Source NetFlow probe for Gigabit Networks

Cisco NetFlow is an industry standard protocol suitable for monitoring network traffic. Although most of high-end network routers support NetFlow, very often flows are computed only on a small portion of the overall traffic due to performance limitation of NetFlow probe implementations. This paper covers the design and implementation of an open source software NetFlow probe designed for handling Gigabit traffic. As nProbe uses little CPU and memory, it has been successfully used to monitor high-speed networks at full wire speed without packet sampling in scenarios where commercial NetFlow probes could not be used due to their limitations. Finally, the paper shows how nProbe has been successfully integrated into an embedded computer named nBox